The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer

Physics in Medicine and Biology

Volumn 48, Issue 4, 2003, Pages 507-522

  Lindsay, Patricia E ^a   Moiseenko, V V ^a   Van Dyk, J ^a   Battista, J J ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOSIMETRY; RADIOTHERAPY; TUMORS;

BRACHYTHERAPY;

IMPLANTS (SURGICAL);

IODINE 125;

ARTICLE; BRACHYTHERAPY; CALCULATION; CANCER CONTROL; CONTROLLED STUDY; DOSIMETRY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION BEAM; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOLOGICAL PARAMETERS; RADIOSENSITIVITY; SENSITIVITY ANALYSIS; TREATMENT PLANNING;

BRACHYTHERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0037458373     PISSN: 00319155     EISSN: None     Source Type: Journal    
DOI: 10.1088/0031-9155/48/4/307     Document Type: Article

References (30)

1. 103Pd Phys. Med. Biol. 46 2557-69
2. Brenner D J and Hall E J 1999 Fractionation and protraction for radiotherapy of prostate carcinoma Int. J. Radiat. Oncol. Biol. Phys. 43 1095-1101
3. Brenner D J and Hall E J 2000 In response to Drs King and Mayo: low α/β values for prostate appear to be independent of modeling details Int. J. Radiat. Oncol. Biol. Phys. 47 538-9
4. Brenner D J, Martinez A A, Edmundson G K, Mitchell C, Thames H D and Armour E P 2002 Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue Int. J. Radiat. Oncol. Biol. Phys. 52 6-13
5. Chen M E, Johnston D A, Tang K, Babaian R J and Troncoso P 2000 Detailed mapping of prostate carcinoma foci Cancer 89 1800-9
6. Dale R G 1985 The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy Br. J. Radiol. 58 515-28
7. Dale R G and Jones B 1998 The clinical radiobiology of brachytherapy Br. J. Radiol. 71 465-83
8. Dale R G and Jones B 2002 Is the α/β for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys. 52 1427-28
9. D'Souza W D and Thames H D 2001 Is the α/β ratio for prostate cancer low? Int. J. Radiat. Oncol. Biol. Phys. 51 1-3
10. Duchesne G M and Peters L J 1999 What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy Int. J. Radiat. Oncol. Biol. Phys. 44 747-8
11. Fowler J, Chappell R and Ritter M 2001 Is α/β for prostate tumors really low? Int. J. Radiat. Oncol. Biol. Phys. 50 1021-31
12. Fowler J F 1999 The linear-quadratic formula and progress in fractionated radiotherapy Br. J. Radiol. 62 679-94
13. Haustermans K M and Fowler J F 2000 A comment of proliferation rates in human prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 48 303
14. Haustermans K M, Hofland I, Van Poppel H, Oyen R, Van de Voorde W, Begg A C and Fowler J F 1997 Cell kinetic measurements in prostate cancer Int. J. Radiat. Oncol. Biol. Phys. 37 1067-70
15. Kellerer A M and Rossi H H 1972 The theory of dual radiation action Curr. Top. Radiat. Res. Q. 8 85
16. King C R, DiPetrillo T A and Wazer D E 2000 Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT and brachytherapy from radiobiologic models Int. J. Radiat. Oncol. Biol. Phys. 46 165-72
17. King C R and Fowler J F 2001 A simple analytic derivation suggests that prostate cancer α/β ratio is low Int. J. Radiat. Oncol. Biol. Phys. 51 213-4
18. King C R and Mayo C S 2000 Is the prostrate α/β ratio of 1.5 from Brenner & Hall a modeling artifact? Int. J. Radiat. Oncol. Biol. Phys. 47 536-8
19. Ling C C, Li W X and Anderson L L 1995 The relative biological effectiveness of 1-125 and Pd-103 Int. J. Radiat. Oncol. Biol. Phys. 32 373-8
20. 125I seeds Int. J. Radiat. Oncol. Biol. Phys. 28 971-8
21. Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R and Yu Y 2000 The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis Int. J. Radiat. Oncol. Biol. Phys. 46 221-30
22. Niemierko A 1997 Reporting and analysing dose distributions: a concept of equilavent uniform dose Med. Phys. 24 103-10
23. Potters L, Cao Y, Calugaru E, Torre T, Fearn P and Wang X H 2001 A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy Int. J. Radiat. Oncol. Biol. Phys. 50 605-14
24. Roberts S A and Hendry J H 1998 A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity Int. J. Radiat. Oncol. Biol. Phys. 41 689-99
25. Scalliet P and Wambersie A 1987 Which RBE for iodine 125 in clinical applications? Radiother. Oncol. 9 221-30
26. Stock R G, Stone N N, Tabert A, Iannuzzi C and DeWyngaert J K 1998 A dose-response study for I-125 prostate implants Int. J. Radiat. Oncol. Biol. Phys. 41 101-8
27. Tome W A and Fowler J F 2002 On cold spots in tumor subvolumes Med. Phys. 29 1590-8
28. 192Ir brachytherapy sources Int. J. Radiat. Oncol. Biol. Phys. 36 689-97
29. 103Pd brachytherapy sources using the concept of proximity function Med. Phys. 25 2186-9
30. Zellmer D L, Shadley J D and Gillin M T 1994 Comparison of measured biological response and predictions from microdosimetric data applicable to brachytherapy Radiat. Prot. Dosim. 52 395-403